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Abstract 
The plastic component bisphenol A (BPA) is suspected to exert deleterious effects towards 
human health and targets various cellular and molecular pathways, including activity of ATP-
binding cassette drug transporters. The present study was designed to determine whether BPA 
and some derivatives, like its substitutes bisphenol F (BPF) and bisphenol S (BPS) and the 
flame retardant tetrabromobisphenol (TBBPA), may additionally interact with solute carrier 
(SLC) drug transporters. Activities of the various following SLC transporters were inhibited 
in a major way (by more than 60%) by 100 µM bisphenols: OCT1 and MATE1 (by BPA and 
TBBPA), OATP1B1 and OATP2B1 (by BPA, BPF and TBBPA), OATP1B3 and NTCP (by 
TBBPA) and OAT3 (by BPA, BPF, BPS and TBBPA); by contrast, activities of other 
transporters were not impacted (MATE2-K) or were stimulated (notably OCT1 by BPS and 
OCT2 by BPF).  Transporter inhibitions due to bisphenols were concentrations-dependent, 
with half maximal inhibitory concentrations (IC50) ranging from 0.52 µM to 73.5 µM. BPA 
was finally shown to be not transported by OAT3, although inhibiting this transporter in a 
competitive manner. Taken together, these data indicate that bisphenols interact with SLC 
transporters, at concentration levels however higher than those occurring in response to 
environmental exposure in humans.   
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1. Introduction 
Bisphenol A (BPA) is a synthetic chemical compound, largely used as a monomere in 
the production of polycarbonate plastics and epoxy resins, and by this way among the highest-
volume chemicals produced worldwide. BPA is found in many consumer products, including 
food containers, paper products like thermal paper, water pipes and medical equipment 
(Halden, 2010). Humans are consequently widely exposed to this chemical, via dietary and 
non-dietary sources (Kang et al., 2006). Importantly, such an exposure is now thought to 
cause various deleterious effects for health (Rochester, 2013; Srivastava et al., 2015). BPA, 
through acting as a xeno-estrogen (Ben-Jonathan and Steinmetz, 1998), may thus exert 
reproductive and developmental toxicity (Golub et al., 2010; Peretz et al., 2014); it may also 
contribute to metabolic and cardiovascular diseases (Lang et al., 2008), may impair immunity 
(Jochmanova et al., 2015) and is suspected to have carcinogenic properties (Thompson et al., 
2015). Such toxic effects have led to governmental restrictive regulations on the production 
and usage of BPA in North America and the European Union (Birnbaum et al., 2013). This 
also stimulates the development and production of alternative substances to replace BPA in a 
myriad of applications. Among such BPA substitutes, bisphenol analogues like bisphenol F 
(BPF) and bisphenol S (BPS) are major ones, even if they exhibited similar estrogenic and/or 
antiandrogenic activities than those of BPA (Chen et al., 2016). Endocrine-disrupting effects 
have additionally been reported for tetrabromobisphenol A (TBBPA), another bisphenol 
derivative, widely used as a brominated flame retardant in printed circuit boards and to which 
humans are also highly exposed (Birnbaum and Staskal, 2004).  
 Besides classical nuclear estrogen receptor alpha and beta, various molecular targets of 
BPA have been described, notably at the plasma membrane level. BPA thus interacts with ion 
channels and ATP-binding cassette (ABC) membrane transporters (Deutschmann et al., 2013; 
Soriano et al., 2016), suggesting that transport across plasma membrane may represent one of 
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the cellular process with which bisphenols interfere. In this context, it is noteworthy that main 
ABC drug efflux pumps have been shown to be targeted by bisphenols. Breast cancer 
resistance protein (BCRP/ABCG2) activity is thus inhibited by BPA and TBBPA; TBBPA 
additionally inhibits P-glycoprotein (P-gp/ABCB1) and multidrug resistance-associated 
protein (MRP) 1 (ABCC1) and MRP4 (ABCC4) (Dankers et al., 2013), whereas, by contrast, 
BPA stimulates P-gp activity (Jin and Audus, 2005), without however affecting P-gp 
expression (Peyre et al., 2014). Importantly, BPA, but not TBBPA, is transported by BCRP 
(Dankers et al., 2013); BPA is also a potential substrate for MRP2 (ABCC2) and MRP3 
(ABCC3) (Mazur et al., 2012). These drug efflux pumps may therefore participate in the 
elimination of BPA and conjugated BPA metabolites, notably at the liver level (Moscovitz et 
al., 2016). 
In addition to interacting with membrane ABC drug transporters, bisphenols may 
interfere with activity of solute carrier (SLC) drug transporters. The fact that BPA has been 
recently shown to inhibit activity of organic anion transporting polypeptide (Oatp/Slco) 1d1 
(Slco1d1) in zebrafish fully supports this hypothesis (Popovic et al., 2014). Such potential 
interactions of bisphenols with SLC transporters remain however very poorly characterized, 
although SLC drug transporters represents key-actors of xenobiotic elimination pathway, 
notably in the liver and kidney where most of them primarily mediate drug uptake and whose 
inhibition may be the source of drug-drug interactions (Giacomini et al., 2010). The present 
study was therefore designed to analyze the possible interactions of various environmentally 
relevant bisphenols, i.e., BPA, BPF, BPS and TBBPA, with activities of main human SLC 
drug transporters notably expressed in the liver, i.e., organic cation transporter (OCT) 1 
(SLC22A1), organic anion transporting polypeptide (OATP) 1B1 (SLCO1B1), OATP1B3 
(SLCO1B3), OATP2B1 (SLCO2B1), sodium/taurocholate co-transporting polypeptide 
(NTCP/SLC10A1) and multidrug and toxin extrusion protein (MATE) 1 (SLC47A1), or in 
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the kidney, i.e., OCT2 (SLC22A2), organic anion transporter (OAT) 1 (SLC22A6), OAT3 
(SLC22A7) and MATE2-K (SLC47A2). Our data indicate that most of these SLC transporters 
constitute targets for bisphenols, especially for BPA and TBBPA.     
 
2. Materials and Methods 
2.1. Chemicals and reagents 
BPA, BPF, BPS and TBBPA were provided by Sigma-Aldrich (Saint-Quentin 
Fallavier, France), as well as verapamil, probenecid, fluorescein, bromosulfophthalein (BSP) 
and amitriptyline. Chemical structures of bisphenols are shown in Fig. 1. Some of their basic 
molecular properties, including molecular weight, LogP predicted using the XLogP3 method, 
counts of hydrogen bond donors, hydrogen bond acceptors and rotatable bonds, and 
topological surface area, were given by PubChem database 
(https://pubchem.ncbi.nlm.nih.gov/) and are indicated in Supplementary Table 1. [1-14C]-
Tetra-ethylammonium bromide (TEA) (sp. act. 3.5 mCi/mmol), [6, 7-3H(N)] estrone-3-sulfate 
(E3S) (sp. act. 57.3 Ci/mmol), [3H(G)]-taurocholic acid (sp. act. 5.0 Ci/mmol), P-[glycyl-1-
14C]-aminohippuric acid (PAH) (sp. act. 50.4 Ci/mmol) and [bis 2,6-3H]-BPA (sp. act. 51.0 
Ci/mmol) were from Perkin-Elmer (Boston, MA, USA). All other chemicals and reagents 
were commercial products of the highest purity available.  
 
2.2. Cell culture 
HEK293 cells overexpressing OCT1 (HEK-OCT1 cells), OCT2 (HEK-OCT2 cells), 
MATE1 (HEK-MATE1 cells), MATE2-K (HEK-MATE2-K cells) or NTCP (HEK-NTCP 
cells) and control HEK293 cells (HEK-MOCK cells), whose generation has already been 
described (Jouan et al., 2014; Le Vee et al., 2015), were routinely cultured in DMEM medium 
supplemented with 10% fetal calf serum (v/v), 100 IU/mL penicillin, 100 μg/mL 
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streptomycin, 1% (vol/vol) MEM non-essential amino acids solution (Life Technologies) and 
1 μg/mL insulin. HEK293 cells overexpressing OAT1 (NM_004790) (HEK-OAT1 cells) or 
OAT3 (NM_004254) (HEK-OAT3 cells) were prepared by transduction of HEK293 cells by 
a lentiviral pLV-EF1-hOAT1-hPGK-GFP or pLV-EF1-hOAT3-hPGK-GFP vector, as 
previously reported (Jouan et al., 2014). Construction of the lentiviral vectors, production of 
lentivirus supernatants, transduction of HEK293 cells, cloning and initial characterization of 
HEK-OAT1 and HEK-OAT3 cells were performed by Vectalys (Labège, France). HEK-
OAT1 and HEK-OAT3 were routinely cultured in DMEM medium as described above.  
 OATP1B1-, OATP1B3- and OATP2B1-transfected CHO cells were cultured in 
DMEM-low glucose containing 10 IU/mL penicillin, 10 μg/mL streptomycin, 10% (vol/vol) 
fetal calf serum, 50 µg/mL proline and 500 μg/mL G418, as previously reported (de Graaf et 
al., 2011). 
 Human differentiated hepatoma HepaRG cells (Gripon et al., 2002), which exhibit 
functional expression of OATPs (Le Vee et al., 2006), were routinely cultured in Williams' E 
medium (Life Technologies) supplemented with 10% (vol/vol) fetal calf serum, 100 IU/mL 
penicillin, 100 μg/mL streptomycin, 5 μg/mL insulin, 2 mM glutamine, and 5 x 10–5 M 
hydrocortisone hemisuccinate. Additional culture for two weeks in the same medium 
supplemented with 2% (vol/vol) dimethylsulfoxide was performed in order to get a full 
hepatocytic differentiation of the cells (Le Vee et al., 2006). 
 
2.3. SLC transporter activity assays  
The effects of bisphenols on SLC transporter activities were analyzed through 
determining intracellular accumulation of reference substrates of SLC transporters using a 
well-defined transport medium, as previously reported (Jigorel et al., 2005; Le Vee et al., 
2015). The transport assay medium consisted of 5.3 mM KCl, 1.1 mM KH2PO4, 0.8 mM 
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MgSO4, 1.8 mM CaCl2, 11 mM D-glucose, 10 mM HEPES, and 136 mM NaCl; pH was 
adjusted to 7.4 value, except for the pH-sensitive MATE1 and MATE2-K transport assays for 
which pH was set at 8.4. Cells were first washed with transport assay buffer, then incubated at 
37 °C for 5 min with transport assay buffer containing 40 µM [14C]-TEA (used as a reference 
substrate for OCT1, OCT2, MATE1 and MATE2-K), 3.5 nM [3H]-E3S (used as a reference 
substrate for OATP1B1, OATP2B1 and OAT3), 10 µM fluorescein (used as a reference 
substrate for OATP1B3), 43.4 nM [3H] taurocholate (used as a reference substrate for NTCP) 
or 0.1 µM [14C]-PAH (used as a reference substrate for OAT1), in the absence or presence of 
bisphenols or reference SLC transporter inhibitors. These reference inhibitors were 50 µM 
verapamil (for OCT1, MATE1 and MATE2-K), 100 µM BSP (for OATP1B1 and 
OATP2B1), 10 mM probenecid (for OATP1B3), 2 mM probenecid (for OAT1 and OAT3) 
and 100 µM amitriptyline (for OCT2). Reference inhibition of NTCP activity was done 
through removal of NaCl from transport assay medium and replacing it by 136 mM N-methyl 
glucamine (Jigorel et al., 2005). Cells were next washed twice with ice-cold phosphate-
buffered saline (PBS), and finally lysed in distilled water. Intracellular accumulation of 
radiolabeled substrates was next measured by scintillation counting with a Beckman LS6500 
(Beckman Coulter Inc, Fullerton, CA, USA). Intracellular accumulation of fluorescein was 
determined by spectrofluorimetry using a SpectraMax Gemini SX spectrofluorometer 
(Molecular Devices, Sunnyvale, CA); excitation and emission wavelengths were 485 and 535 
nm, respectively. Values of substrate accumulation were normalized to total protein content, 
determined by the Bradford method (Bradford, 1976). Data were finally expressed as % of 
substrate accumulation in control cells not exposed to reference inhibitor or bisphenols; in this 
context, % of reduction of substrate accumulation was defined as 100% (accumulation in 
control cells) minus % of substrate accumulation in the presence of bisphenol or reference 
inhibitor, whereas % of stimulation of substrate accumulation corresponded to % of substrate 
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accumulation in the presence of bisphenol minus 100 % (accumulation in control cells). Data 
were also alternatively expressed as % of transporter activity found in control cells, arbitrarily 
set at 100%, according to the following equations: 
For OATPs, OATs, OCTs and MATEs:  
% SLC transporter activity =   (A) 
with Accumulationbisphenol = substrate accumulation in the presence of bisphenol, 
Accumulationcontrol = substrate accumulation in control cells and Accumulationreference inhibitor = 
substrate accumulation in the presence of a reference transporter inhibitor. 
For NTCP: 
% NTCP activity =      (B) 
with AccumulationBisphenol = taurocholate accumulation in the presence of bisphenol and 
sodium, AccumulationControl/+Na+ = taurocholate accumulation in control cells in the presence 
of sodium and AccumulationControl/-Na+ = taurocholate accumulation in control cells in the 
absence of sodium. 
 
2.4. BPA accumulation assays 
 HEK-OAT3 cells and control HEK-MOCK cells were incubated at 37 °C for various 
lengths of time (from 1 to 10 min) with transport assay buffer containing 19.6 nM [14C]-BPA. 
Cells were next washed twice with ice-cold PBS, and finally lysed in distilled water. 
Intracellular accumulation of BPA was then measured by scintillation counting as reported 
above.   
 
2.5. Determination of kinetic parameters  
For bisphenols inhibiting SLC drug transporter activity by at least 60 % when initially 
used at 100 µM, transport assays described above were performed in the presence of various 
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concentrations of bisphenols. Half maximal inhibitory concentrations (IC50) were next 
determined using Prism 5.0 software (GraphPad Software, La Jolla, CA, USA) through 
nonlinear regression based on the following four-parameter logistic equation: 
A=         (C) 
where A is the % of SLC transporter activity for a given concentration of bisphenol 
determined as described in equation (A) for OATPs, OATs, OCTs and MATEs and in 
equation (B) for NTCP, [I] is the bisphenol concentration in the medium, and Hill slope is a 
coefficient describing the steepness of the curve.  
 Kinetic parameters of E3S uptake into HEK-OAT3 cells (Km and Vmax) in the absence 
or presence of 50 µM BPA were estimated using Prism 5.0 software through nonlinear 
regression based on the Michaelis-Menten equation: 
𝑣𝑣=      (D) 
 
where v is the initial uptake rate of substrate, [S] is the substrate concentration in the medium, 
Km is the Michaelis–Menten affinity constant, and Vmax is the maximum uptake rate.  
 
2.6. Statistical analysis 
Experimental data were usually expressed as means ± SEM. They were statistically 
analyzed through analysis of variance (ANOVA) followed by the Dunnett’s post-hoc test or 
through the F-test using the Prism 5.0 software. The criterion of significance was p < 0.05.  
 
3. Results 
3.1. Inhibition of organic cation transporter activity by bisphenols 
Effects of BPA, BPF, BPS and TBBPA, each used at 100 µM, on TEA transport 
mediated by the organic cation transporters OCT1, OCT2, MATE1 or MATE2-K were 
determined. As shown in Fig. 2, BPA and TBBPA, like the reference inhibitor verapamil, 
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markedly inhibited uptake of TEA in HEK-OCT1 cells, by more than 80 % when compared to 
uptake in control conditions. BPF also significantly decreased TEA uptake in HEK-OCT1 
cells, but in a more moderately manner (inhibition by 41.6 %), whereas, by contrast, BPS 
stimulated TEA accumulation by 61.9 % (Fig. 2). BPS, and also BPF, additionally stimulated 
TEA accumulation in HEK-OCT2 cells, whereas TBBPA reduced it and BPA was without 
effect (Fig. 2); the percentage of reduction of TEA uptake by TBBPA in HEK-OCT2 cells 
(39.4 %) was however lower than that caused by the reference OCT2 inhibitor amitriptyline 
(87.8 %). TEA uptake in HEK-MATE1 cells was inhibited by all bisphenols (Fig. 2); the 
percentages of these inhibitions by bisphenols ranged from 28.1 % (for BPF) to 66.8 % (for 
TBBPA) and were therefore lower than that caused by verapamil (98.0%) (Fig. 2). None of 
bisphenols impaired TEA accumulation in HEK-MATE2-K cells, in contrast to the reference 
inhibitor verapamil that markedly reduced it by 87.3 % (Fig. 2).  
For inhibitions of TEA accumulation by 100 µM bisphenol reaching at least 60%, IC50 
values towards SLC transporter activities were next determined. As shown in Fig. 3A, BPA 
IC50 towards OCT1 and MATE1 activities were 39.0 and 73.5 µM, respectively.  With respect 
to TBBPA, IC50 values were 37.5 µM (for OCT1 activity) and 23.1 µM (for MATE1 activity) 
(Fig. 3B).  
 
3.2. Inhibition of organic anion transporter activity by bisphenols 
Effects of BPA, BPF, BPS and TBBPA, each used at 100 µM, on OATP-mediated 
uptake of reference substrates were first studied. As shown in Fig. 4A, BPA, BPF and TBPPA 
significantly decreased ES3 accumulation in CHO-OATP1B1 and CHO-OATP2B1 cells, in a 
rather notable manner; the percentages of accumulation decrease were thus comprised 
between 68.9 % (for down-modulation of E3S uptake by BPA in CHO-OATP1B1 cells) and 
87.9  % (for down-modulation of E3S uptake by BPA in CHO-OATP2B1 cells). BPS also 
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reduced E3S uptake in HEK-OATP2B1 cells, but in a weaker manner (reduction by 43.6%); 
by contrast, this bisphenol failed to significantly alter E3S accumulation in HEK-OATP1B1 
cells (Fig. 4A). BPS, in contrast to the reference inhibitor probenecid, did not also affect 
fluorescein uptake in CHO-OATP1B3 cells, whereas BPF significantly enhanced it by 38.2 % 
and BPA and TBBPA reduced it by 49.7 % and 73.8 %, respectively (Fig. 4A). Bisphenols 
were next shown to reduce E3S accumulation in hepatoma HepaRG cells, which 
constitutively display OATP activity (Le Vee et al., 2013); in this context, TBBPA was the 
most active, with an inhibitory effect on E3S uptake similar to that of the reference inhibitor 
BSP (Fig. 4B). 
Effects of BPA, BPF, BPS and TBBPA, each used at 100 µM, on OAT- and NTCP-
mediated uptake of reference substrates were next analyzed. As indicated in Fig. 5A, BPS 
moderately reduced PAH accumulation by 44.1% in HEK-OAT1 cells, whereas BPA 
stimulated it by 49.3% and BPF and TBBPA were without effect. All bisphenols markedly 
decreased E3S uptake in HEK-OAT3 cells, with percentage of inhibition ranging from 79.5 % 
(for BPF) to 94.1 % (for TBBPA) and therefore closed to the percentage of inhibition (97.2 
%) caused by the reference inhibitor BSP (Fig. 5A). TBBPA was finally shown to markedly 
inhibit sodium-dependent accumulation of taurocholate in HEK-NTCP cells by 91.5 %, 
whereas BPA and BPF more modestly decreased it by 44.3 % and 39.2 %, respectively, and 
BPS was without effect (Fig. 5B).  
For inhibitions of reference anionic substrate accumulation by 100 µM bisphenol 
reaching at least 60%, IC50 values towards SLC transporter activities were next determined. 
As shown in Fig. 6A, BPA IC50 values towards OATP1B1, OATP2B1 and OAT3 activities 
were around 9.2-26.4 µM. Those of BPF were 13.4 µM (for OATP1B1), 63.2 µM (for 
OATP2B1) and 26.8 µM (for OAT3) (Fig. 6B), whereas that of BPS toward OAT3 activity 
was 23.3 µM. IC50 values of TBBPA towards OATP1B1, OATP2B1 and OAT3 activities 
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were rather low (between 0.5 and 1 µM), whereas those towards NTCP and OATP1B3 
activities were 4.5 µM and 12.1 µM, respectively (Fig. 7).   
 
3.3. Characterization of OAT3-BPA interaction 
Because OAT3 was the SLC transporter most potently inhibited by BPA (IC50=9.17 
µM; Fig. 6A), we next decided to characterize the nature of its interaction with this SLC 
transporter, primarily expressed by proximal renal cells (Burckhardt and Wolff, 2000). For 
this, we first analyzed the kinetic parameter (Km and Vmax) of E3S uptake by HEK-OAT3 
cells in the absence or presence of 50 µM BPA through non-linear regression of E3S uptake 
in function of E3S concentration using the Michaelis-Menten equation. As indicated in Fig. 8, 
BPA was found to significantly enhance Km without altering Vmax, thus suggesting that it 
inhibited OAT3 activity by a competitive mechanism, possibly through interacting with the 
transport binding site of OAT3. To determine whether BPA may be a substrate for this SLC 
transporter, we next analyzed BPA uptake in HEK-OAT3 and HEK-MOCK cells. Results 
indicated that the two types of cells similarly accumulated BPA, whatever the incubation 
times with BPA (from 1 min to 10 min) (Fig. 9), thus discarding the hypothesis that BPA may 
be transported by OAT3. This conclusion is also supported by the fact that the OAT inhibitor 
probenecid used at 2 mM failed to alter BPA accumulation in HEK-OAT3 cells (data not 
shown). By contrast, HEK-OAT3 cells exhibited marked probenecid-inhibitable uptake of 
E3S when compared to HEK-MOCK cells (Supplementary Fig. 1), thus confirming that 
OAT3 was fully functional in HEK-OAT3 cells.  
 
3.4. Prediction of potential drug-drug interactions due to inhibition of SLC transporters by 
BPA 
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We finally considered whether in vitro inhibition of SLC transporter activities by BPA 
may be relevant in term of drug-drug interactions (DDI). For this, we applied the criteria 
retained by the US Food and Drug Administration (FDA), according to which a potential DDI 
with respect to a drug inhibiting a transporter can be predicted from in vitro data when the 
maximum total plasma (bound plus unbound) concentration (Cmax) of the investigated drug at 
steady state ([I]) divided by its in vitro inhibitory potency (IC50) is greater than or equal to 0.1 
([I]/IC50> 0.1) (Giacomini et al., 2010; Hillgren et al., 2013; Maeda and Sugiyama, 2013). For 
[IBPA], we retained the value of 6.5 nM, that corresponds to the unconjugated BPA Cmax 
recently reported following oral administration of BPA to human volunteers (Thayer et al., 
2015) and the value of 44 nM, that is the upper limit of the range of unconjugated BPA 
concentrations (2.2 nM to 44 nM) measured in blood samples from human populations 
(Vandenberg et al., 2010). None of these two BPA concentration values was predicted to 
cause potential DDI involving OCTs, MATEs, OATPs or OATs transporters, according to the 
FDA criteria (Table 1).   
 
4. Discussion 
 The environmental contaminant BPA has previously been shown to interact with ABC 
drug efflux pumps like P-glycoprotein, MRP2 and BCRP. The data reported in the present 
study indicate that BPA and other bisphenol derivatives such as BPF, BPS and TBBPA can 
also inhibit various human SLC drug transporters, thus highlighting the fact that membrane 
drug transporters represent targets for environmental bisphenols. 
 BPA was thus demonstrated to inhibit activities of various SLC transporters, 
especially those of OCT1, MATE1, OATP1B1, OATP2B1 and OAT3 in transporter-
overexpressing transfected cells; it concomitantly reduced constitutive OATP activity in 
hepatic HepaRG cells, indicating that its inhibitory effects towards SLC transporters were not 
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restricted to transfected cells.  By contrast, BPA failed to impair activities of other SLC 
transporters such as OCT2, MATE2-K, OATP1B3 and OAT1, thus most likely discarding the 
hypothesis of a general and non-discriminating inhibitory effect of BPA towards membrane 
transporter activities. Inhibitory effects of BPA and other bisphenols towards some SLC drug 
transporters can rather be considered as specific, probably reflecting direct and transporter-
dependent interactions of BPA and other bisphenols with substrate and/or regulatory binding 
sites on drug transporters, as classically described for drug transporter inhibitors (Montanari 
and Ecker, 2015). In this context, BPA appears to inhibit OAT3 in a competitive manner, thus 
suggesting that the bisphenol interacts with the substrate drug binding site of this transporter. 
However, BPA accumulation was similar in HEK-OAT3 and HEK-MOCK cells, indicating 
that BPA is not transported by OAT3, although interacting with the substrate drug binding.  
Non-competitive mechanism may also additionally account for inhibition of some transporters 
by BPA; the fact that BPA acts as an uncompetitive inhibitor of Oatp1d1 in Zebrafish 
supports this hypothesis (Popovic et al., 2014). In addition, it is noteworthy that BPA 
increased activity of OAT1. Such a cis-stimulation of SLC transporter activity has been 
already described for various chemicals (De Bruyn et al., 2013) and is also reported in the 
present study for other bisphenols such as BPF, that stimulated activity of OCT2 and 
OATP1B3, and BPS, that enhanced that of OCT1 and OCT2; in the same way, BPA has been 
previously shown to stimulate activity of the ABC efflux pump P-glycoprotein in placental 
cells (Jin and Audus, 2005). The molecular mechanisms that underlying such cis-stimulatory 
effects remain however yet very poorly characterized; they can reflect specific positive 
interactions with putative regulatory (or allosteric) binding sites on transporters, resulting in 
increased transport activity (Jin and Audus, 2005). With respect to SLC transporters, e.g. 
OATPs many of them have more than one binding site, which may mutually modulate each 
other : Hagenbuch and Stieger, Mol Asp Med 34: 396-412, 2014; Stieger and Hagenbuch, 
15 
 
Curr Top Membr 73: 205-232, 2014. Futures studies are therefore needed to more extensively 
characterize the exact mechanisms by which BPA differently interacts with some human SLC 
transporters. 
 Besides BPA, BPA substitutes like BPF and BPS and the brominated bisphenol 
TBBPA, used as flame retardant, also inhibited activities of SLC transporters. Among these 
bisphenols, TBBPA was the most potent inhibitor, acting towards the greatest number of 
transporters (activities of only OAT1 and MATE2-K were not impacted) and displaying low 
IC50 values, less than 1 µM for OATP1B1, OATP2B1 and OAT3. By contrast, OAT3 was the 
only transporter markedly inhibited by BPS, which thus appears as the less inhibitory 
bisphenol analyzed in the present study, while the inhibitory profile of BPF was relatively 
closed to that of BPA. Physico-chemical features differentially displayed by bisphenols may 
basically contribute to their various inhibitory effects towards SLC transporters. In this 
context, among basic molecular descriptors of bisphenols (Supplementary Table 1), 
hydrophobicity/LogP may be an important parameter to consider.  Indeed, hydrophobicity has 
been reported to be one of key molecular descriptors for inhibition of various SLC 
transporters such as OAT3 (Duan et al., 2012), OCT1 (Ahlin et al., 2008) and OATP1B1 (De 
Bruyn et al., 2013), that are markedly inhibited by TBBPA, which, according to the calculated 
LogP value, is the most hydrophobic bisphenol (Supplementary Table 1). By contrast, 
hydrophobicity is not a molecular descriptor associated with blockage of OAT1 (Duan et al., 
2012), which is not impacted by TBBPA. Further studies are however likely required to 
analyze quantitative structure-activity relationships for bisphenols-mediated inhibition of SLC 
transporters in a more detailed and accurate manner, knowing that a single molecular 
descriptor is not thought to be sufficient to appropriately describe binding to SLC transporters 
(Astorga et al., 2012).  
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 The putative relevance of the SLC transporter inhibitions described in the present 
paper to human exposure to environmental bisphenols is probably a key-point that has to be 
considered. Inhibition of SLC transporters by BPA is very unlikely to cause DDI according to 
FDA criteria. This likely reflects the rather low plasma concentrations of BPA in humans, 
which are in the 1-44 nM range, owing to extensive intestinal and hepatic first-pass 
metabolism producing BPA-glucuronide (Thayer et al., 2015). In the same way, BPA-
mediated SLC transporter inhibition may be presumed to have no consequence in terms of in 
vivo membrane transport of hormones like estrogens and thyroid hormones, which are notably 
handled by OATPs (Obaidat et al., 2012). A contribution of putative impairment of hormone 
transport in target cells or detoxifying organs like liver to known endocrine disruptive effects 
of BPA can therefore likely be discarded. With respect to TBBPA plasma concentrations in 
humans, they are either below the limit of quantification or very low, i.e., less than 40 pM, 
reflecting rapid metabolism of TBBPA (Kibakaya et al., 2009; Schauer et al., 2006). Minimal 
concentrations of TBBPA (in the 0.5-1 µM range) required to inhibit SLC transporters  can 
therefore not be reached in vivo, making very unlikely any DDI or perturbation of membrane 
transport of physiological substrates like hormones or bile acid due to TBBPA. Similarly, 
although plasma concentrations of BPF and BPS have not been yet characterized in humans, 
they may be hypothesized to be not sufficient to reach levels consistent with SLC transporter 
inhibition. It should however be kept in mind that humans are likely to be exposed not only to 
a single bisphenol, but to other contaminants and xenobiotics, that may also interact with drug 
transporters (Fardel et al., 2012), as recently demonstrated for notably organochlorine 
pesticides (Bucher et al., 2014), polychlorinated biphenyls (Nicklisch et al., 2016), diesel 
exhaust particle components (Le Vee et al., 2015) and perfluorinated surfactants (Nakagawa 
et al., 2009).  Plasma levels of bisphenols in association with those of other pollutants, may 
therefore be sufficient to contribute to synergic or additive inhibitory effects towards drug 
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transporters, as already described for pesticide combinations (Pivcevic and Zaja, 2006). In 
addition, concentrations of bisphenols may be much higher in the gastro-intestinal tract 
(before first-pass metabolism) than in plasma, and SLC transporters notably expressed at the 
intestinal level, especially OATP2B1 and OCT1 (Giacomini et al., 2010), may therefore be 
hypothesized to be inhibitable by ingested bisphenols.  
 In summary, BPA and other environmental bisphenol derivatives, including TBBPA, 
were shown to down-modulate in vitro activity of various human SLC drug transporters. Such 
inhibitions of drug transporters occur however for relatively elevated concentrations of 
bisphenols (in the µM range), much higher than plasma concentrations observed in human 
populations (in the nM range for BPA and in the pM range for TBBPA). Such data make 
unlikely the fact that in vivo exposure to environmental bisphenols may lead to inhibition of 
SLC transporters in humans and, by this way to DDI or adverse effects, excepted for the 
gastrointestinal tract where sufficient concentrations of bisphenols may be reached.  
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Table 1: Prediction of potential drug-drug interactions (DDI) for BPA-mediated inhibitions of 
SLC drug transporters according to FDA criteriaa 
SLC transporter 
Effect of BPA 
on transporter 
activity 
Ratio [IBPA]/IC50 Prediction of potential 
DDI according to FDA 
criteria [IBPA]=6.5 nM
b [IBPA]=44 nMc 
OCT1 Inhibition (IC50=39.0 µM) 0.00017 0.00111 No DDI 
OCT2 No effect NDd ND No DDI 
MATE1 Inhibition (IC50=73.5 µM) 
0.00009 0.00060 No DDI 
MATE2K No effect ND ND No DDI 
OATP1B1 Inhibition (IC50=20.4 µM) 
0.00032 0.00216 No DDI 
OATP1B3 No effect ND ND No DDI 
OATP2B1 Inhibition (IC50=26.4 µM) 
0.00025 0.00167 No DDI 
OAT1 No effect ND ND No DDI 
OAT3 Inhibition (IC50=9.2 µM) 
0.00071 0.00478 No DDI 
aFDA criteria: a potential clinical DDI may be predicted when [I]/IC50 > 0.1 
bBPA Cmax according to Thayer et al., 2015 
cUpper limit of the range of BPA concentrations reported in the blood of human populations according 
to (Vandenberg et al., 2010) 
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dND, not determinable 
 
 
 
 
 
  
 
 
Legends to figures 
 
Fig. 1. Chemical structures of bisphenols. 
 
Fig. 2. Effects of bisphenols on OCT1, OCT2, MATE1 and MATE2-K activities. 
OCT- and MATE-overexpressing HEK293 cell clones were incubated at 37°C for 5 min with 
the radiolabeled reference substrate TEA in the absence (untreated) or presence of reference 
inhibitors (50 µM verapamil for OCT1, MATE1 and MATE2-K and 100 µM amitriptyline for 
OCT2) or of bisphenols, each used at 100 µM. After washing, intracellular uptake of TEA 
was determined by scintillation counting and normalized to total cellular protein content. Data 
are the means + SEM of at least three independent experiments. *, p<0.05 when compared to 
control untreated cells. 
 
Fig. 3. Concentration-dependent effects of (A) BPA and (B) TBBPA towards OCT1 and 
MATE1 activities. 
OCT1 and MATE1 activities were determined in the absence or presence of various 
concentrations of (A) BPA or (B) TBBPA, as described in Materials and Methods. Data are 
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expressed as percentages of transporter activity found in control untreated cells, arbitrarily set 
at 100%; they are the means + SEM of three independent assays. IC50 values are indicated at 
the top of graphs.  
 
Fig. 4. Effects of bisphenols on OATP activities. 
(A) OATP-overexpressing CHO cell clones were incubated at 37°C for 5 min with reference 
substrates (radiolabeled E3S for OATP1B1 and OATP2B1 and fluorescein for OATP1B3)  in 
the absence (untreated) or presence of reference OATP inhibitors (100 µM BSP for 
OATP1B1 and OATP2B1 and 2 mM probenecid for OATP1B3) or of bisphenols, each used 
at 100 µM. After washing, intracellular uptake of substrates was determined by scintillation 
counting (E3S) or spectrofluorimetry (OATP1B3) and normalized to total cellular protein 
content. Data are the means + SEM of at least three independent experiments. *, p<0.05 when 
compared to control untreated cells. (B) HepaRG cells were incubated with E3S in the 
absence or presence of 100 µM BSP or of bisphenols, as described above.  After washing, 
intracellular uptake of E3S was determined by scintillation counting and normalized to total 
cellular protein content. Data are the means + SEM of three independent experiments. *, 
p<0.05 when compared to control untreated cells. 
 
Fig. 5. Effects of bisphenols on OAT and NTCP activities. 
(A) OAT-overexpressing HEK293 cell clones were incubated at 37°C for 5 min with 
radiolabeled reference substrates (PAH for OAT1 and E3S for OAT3) in the absence 
(untreated) or presence of the OAT inhibitor probenecid (2 mM) or of bisphenols, each used 
at 100 µM. (B) HEK-NTCP cells were incubated at 37°C for 5 min with taurocholate in 
sodium-containing medium  in the absence (untreated) or presence of bisphenols, each used at 
100 µM; reference inhibition of NTCP activity was done in parallel through removal of 
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sodium from transport assay medium. (A, B) After washing, intracellular uptake of substrates 
was determined by scintillation counting and normalized to total cellular protein content. Data 
are the means + SEM of three independent experiments. *, p<0.05 when compared to control 
untreated cells. 
 
Fig. 6. Concentration-dependent effects of (A) BPA and (B) (BPF) towards OATP1B1, 
OATP2B1 and OAT3 activities and of (C) BPS towards OAT3 activity.  
Transporter activities were determined in the absence or presence of various concentrations of 
(A) BPA, (B) BPF and (C) BPS, as described in Materials and Methods. Data are expressed as 
percentages of transporter activity found in control untreated cells, arbitrarily set at 100%; 
they are the means + SEM of three independent assays. IC50 values are indicated at the top of 
graphs.  
 
Fig. 7. Concentration-dependent effects of TBBPA towards OATP1B1, OATP1B3, 
OATP2B1, OAT3 and NTCP activities.  
Transporter activities were determined in the absence or presence of various concentrations of 
TBBPA, as described in Materials and Methods. Data are expressed as percentages of 
transporter activity found in control untreated cells, arbitrarily set at 100%; they are the means 
+ SEM of three independent assays. IC50 values are indicated at the top of graphs. 
 
Fig. 8. Effects of BPA on kinetic parameters of E3S accumulation in HEK-OAT3 cells. 
HEK-OAT3 cells were incubated with increasing concentrations of E3S in the absence or 
presence of 50 μM BPA for 5 min. E3S uptake velocity (VE3S) was next fitted to [E3S] 
according to the Michaelis-Menten equation, in order to determine Km and Vmax values 
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(indicated at the top of the graph). Data are the mean ± S.E.M. of three independent 
experiments.*, p<0.05 when compared to control cells not exposed to BPA. 
 
Fig. 9. Intracellular uptake of BPA in HEK-MOCK and HEK-OAT3 cells. 
HEK-MOCK and HEK-OAT3 cells were incubated with radiolabeled BPA at 37°C for 
various length of times (from 1 min to 10 min). After washing, intracellular uptake of BPA 
was determined by scintillation counting and normalized to total cellular protein content. Data 
are the means + SEM of three independent experiments. NS, not statistically significant. 
 
